FDA's continuing efforts to educate patients on known risk of lymphoma from breast implants

FDA's continuing efforts to educate patients on known risk of lymphoma from breast implants

The Food and Drug Administration (FDA) wants to increase awareness about an association between all breast implants, regardless of filling or texture, and Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL). The FDA received reports indicating that patients with breast implants have an increased risk of developing this disease within the scar capsule adjacent to the implant.
 
We want all healthcare providers to be aware of BIA-ALCL, particularly in patients with new swelling, lumps, or pain around breast implants, to expedite diagnosis of this malignancy. We are also asking health care providers to report to the FDA cases of BIA-ALCL in patients with breast implants. This includes reporting individual cases as well as rates you may have experienced during your practice.

• Read the full Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) Letter to Health Care Providers
• Read the FDA Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on agency’s continuing efforts to educate patients on known risk of lymphoma from breast implants https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm630895.htm

Visit FDA’s Breast Implants webpage for more information https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/default.htm